Alpha-galactosyl epitope (Alpha-gal)

The alpha-gal epitope (Gal-alpha-1,3-Gal-beta-1,4-GlcNAc-R) is a carbohydrate structure expressed on the cell surfaces of non-primate mammals and New World monkeys, but is absent in humans due to the evolutionary inactivation of the alpha-1,3-galactosyltransferase (GGTA1) gene (Galili, 2013, Immunology and Cell Biology). Because of this absence, humans naturally produce high levels of anti-Gal antibodies, representing about 1% of total serum IgG, in response to alpha-gal epitopes on gut microbiota (Galili, 2023, Antibodies). In cancer immunotherapy, alpha-gal glycolipids or glycoproteins are used to decorate tumor cell membranes, making them targets for these pre-existing natural antibodies. The binding of anti-Gal to alpha-gal on tumor cells triggers complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) (Galili, 2004, Trends in Molecular Medicine). Crucially, this interaction also promotes the opsonization of tumor cells, significantly enhancing their uptake by dendritic cells and subsequent presentation of tumor-associated antigens to T cells, effectively creating an in situ autologous tumor vaccine (Galili, 2013). Clinical applications have included the development of "HyperAcute" vaccines, such as algenpantucel-L, which consist of irradiated allogeneic tumor cells modified to express alpha-gal epitopes (Hardacre et al., 2013, Journal of Gastrointestinal Surgery).

Other names

Gal-alpha-1,3-Gal-beta-1,4-GlcNAc-RAlpha-gal epitopeGalili antigenAlpha-1,3-galactosyl epitopeAlpha-gal glycolipid

The mechanism involves the binding of natural circulating anti-Gal antibodies to alpha-gal epitopes artificially introduced onto tumor cell membranes. This binding initiates the classical complement pathway, leading to tumor cell lysis, and recruits effector cells for antibody-dependent cellular cytotoxicity (ADCC). Additionally, the anti-Gal-coated tumor cells are efficiently phagocytosed by antigen-presenting cells (APCs) via Fc-gamma receptor interaction, which facilitates the processing and presentation of tumor-specific antigens to T cells, inducing a systemic anti-tumor immune response (Galili, 2013, Immunology and Cell Biology; Galili, 2004, Trends in Molecular Medicine).